201 related articles for article (PubMed ID: 25246592)
21. IL-6R/STAT3/miR-204 feedback loop contributes to cisplatin resistance of epithelial ovarian cancer cells.
Zhu X; Shen H; Yin X; Long L; Chen X; Feng F; Liu Y; Zhao P; Xu Y; Li M; Xu W; Li Y
Oncotarget; 2017 Jun; 8(24):39154-39166. PubMed ID: 28388577
[TBL] [Abstract][Full Text] [Related]
22. Cellular transcriptomics: gelsolin negatively regulates the expression of apoptosis-associated genes and inhibits apoptosis in hepatocarcinoma cells.
Zhou Y; Deng X; Ma X; Zang N; Li H; Li G; Li D; Li C; Huang W; He M
Int J Clin Exp Pathol; 2015; 8(11):13871-85. PubMed ID: 26823700
[TBL] [Abstract][Full Text] [Related]
23. Possible role of FLICE-like inhibitory protein (FLIP) in chemoresistant ovarian cancer cells in vitro.
Abedini MR; Qiu Q; Yan X; Tsang BK
Oncogene; 2004 Sep; 23(42):6997-7004. PubMed ID: 15258564
[TBL] [Abstract][Full Text] [Related]
24. Downregulation of miR-130a contributes to cisplatin resistance in ovarian cancer cells by targeting X-linked inhibitor of apoptosis (XIAP) directly.
Zhang X; Huang L; Zhao Y; Tan W
Acta Biochim Biophys Sin (Shanghai); 2013 Dec; 45(12):995-1001. PubMed ID: 24145606
[TBL] [Abstract][Full Text] [Related]
25. [Inhibition of mitochondrial Smac release by Akt in chemoresistant ovarian cancer cells].
Yang XK; Wang JD; Wang SY; Zhang YX
Zhonghua Zhong Liu Za Zhi; 2008 Apr; 30(4):259-62. PubMed ID: 18788627
[TBL] [Abstract][Full Text] [Related]
26. Sensitization of p53-mutated epithelial ovarian cancer to CD95-mediated apoptosis is synergistically induced by cisplatin pretreatment.
Bagnoli M; Balladore E; Luison E; Alberti P; Raspagliesi F; Marcomini B; Canevari S; Mezzanzanica D
Mol Cancer Ther; 2007 Feb; 6(2):762-72. PubMed ID: 17308072
[TBL] [Abstract][Full Text] [Related]
27. Ovarian serous carcinomas acquire cisplatin resistance and increased invasion through downregulation of the high-temperature-required protein A2 (HtrA2), following repeated treatment with cisplatin.
Soyama H; Miyamoto M; Takano M; Aoyama T; Matsuura H; Sakamoto T; Takasaki K; Kuwahara M; Kato K; Yoshikawa T; Iwahashi H; Tsuda H; Furuya K
Med Oncol; 2017 Nov; 34(12):201. PubMed ID: 29168038
[TBL] [Abstract][Full Text] [Related]
28. Expression of miR-224-5p is associated with the original cisplatin resistance of ovarian papillary serous carcinoma.
Zhao H; Bi T; Qu Z; Jiang J; Cui S; Wang Y
Oncol Rep; 2014 Sep; 32(3):1003-12. PubMed ID: 25017423
[TBL] [Abstract][Full Text] [Related]
29. IRF-1 expression is induced by cisplatin in ovarian cancer cells and limits drug effectiveness.
Pavan S; Olivero M; Corà D; Di Renzo MF
Eur J Cancer; 2013 Mar; 49(4):964-73. PubMed ID: 23079474
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of AKT sensitizes chemoresistant ovarian cancer cells to cisplatin by abrogating S and G2/M arrest.
Zhang D; Piao HL; Li YH; Qiu Q; Li DJ; Du MR; Tsang BK
Exp Mol Pathol; 2016 Jun; 100(3):506-13. PubMed ID: 27163202
[TBL] [Abstract][Full Text] [Related]
31. Resistance to Fas-mediated apoptosis in malignant tumours is rescued by KN-93 and cisplatin via downregulation of c-FLIP expression and phosphorylation.
Yang BF; Xiao C; Li H; Yang SJ
Clin Exp Pharmacol Physiol; 2007 Dec; 34(12):1245-51. PubMed ID: 17973862
[TBL] [Abstract][Full Text] [Related]
32. c-FLIPL expression defines two ovarian cancer patient subsets and is a prognostic factor of adverse outcome.
Bagnoli M; Ambrogi F; Pilotti S; Alberti P; Ditto A; Barbareschi M; Galligioni E; Biganzoli E; Canevari S; Mezzanzanica D
Endocr Relat Cancer; 2009 Jun; 16(2):443-53. PubMed ID: 19321593
[TBL] [Abstract][Full Text] [Related]
33. Gelsolin inhibits malignant phenotype of glioblastoma and is regulated by miR-654-5p and miR-450b-5p.
Zhang J; Furuta T; Sabit H; Tamai S; Jiapaer S; Dong Y; Kinoshita M; Uchida Y; Ohtsuki S; Terasaki T; Zhao S; Nakada M
Cancer Sci; 2020 Jul; 111(7):2413-2422. PubMed ID: 32324311
[TBL] [Abstract][Full Text] [Related]
34. Repression of GRIM19 expression potentiates cisplatin chemoresistance in advanced bladder cancer cells via disrupting ubiquitination-mediated Bcl-xL degradation.
Ni F; Yan CY; Zhou S; Hui PY; Du YH; Zheng L; Yu J; Hu XJ; Zhang ZG
Cancer Chemother Pharmacol; 2018 Oct; 82(4):593-605. PubMed ID: 30032449
[TBL] [Abstract][Full Text] [Related]
35. ATF3 suppresses metastasis of bladder cancer by regulating gelsolin-mediated remodeling of the actin cytoskeleton.
Yuan X; Yu L; Li J; Xie G; Rong T; Zhang L; Chen J; Meng Q; Irving AT; Wang D; Williams ED; Liu JP; Sadler AJ; Williams BR; Shen L; Xu D
Cancer Res; 2013 Jun; 73(12):3625-37. PubMed ID: 23536558
[TBL] [Abstract][Full Text] [Related]
36. BMP-4 expression has prognostic significance in advanced serous ovarian carcinoma and is affected by cisplatin in OVCAR-3 cells.
Laatio L; Myllynen P; Serpi R; Rysä J; Ilves M; Lappi-Blanco E; Ruskoaho H; Vähäkangas K; Puistola U
Tumour Biol; 2011 Oct; 32(5):985-95. PubMed ID: 21674241
[TBL] [Abstract][Full Text] [Related]
37. Cisplatin (CDDP) sensitizes human osteosarcoma cell to Fas/CD95-mediated apoptosis by down-regulating FLIP-L expression.
Kinoshita H; Yoshikawa H; Shiiki K; Hamada Y; Nakajima Y; Tasaka K
Int J Cancer; 2000 Dec; 88(6):986-91. PubMed ID: 11093825
[TBL] [Abstract][Full Text] [Related]
38. Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers.
Liu G; Yang D; Rupaimoole R; Pecot CV; Sun Y; Mangala LS; Li X; Ji P; Cogdell D; Hu L; Wang Y; Rodriguez-Aguayo C; Lopez-Berestein G; Shmulevich I; De Cecco L; Chen K; Mezzanzanica D; Xue F; Sood AK; Zhang W
J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25995442
[TBL] [Abstract][Full Text] [Related]
39. Cisplatin resistance in an ovarian carcinoma is associated with a defect in programmed cell death control through XIAP regulation.
Mansouri A; Zhang Q; Ridgway LD; Tian L; Claret FX
Oncol Res; 2003; 13(6-10):399-404. PubMed ID: 12725530
[TBL] [Abstract][Full Text] [Related]
40. Side population is increased in paclitaxel-resistant ovarian cancer cell lines regardless of resistance to cisplatin.
Kobayashi Y; Seino K; Hosonuma S; Ohara T; Itamochi H; Isonishi S; Kita T; Wada H; Kojo S; Kiguchi K
Gynecol Oncol; 2011 May; 121(2):390-4. PubMed ID: 21272926
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
